Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.41 |
| ▸ | PARP1 | P09874 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | GPR3 | P46089 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 2/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4288877 | 0.82 | PDE10A (0.44) | ALDH1A1KDM4EMAPTPDE10AHPGD | |
| SCHEMBL6081732 | 0.82 | PDE10A (0.44) | ALDH1A1KDM4EMAPTPDE10AHPGD | |
| SCHEMBL11214071 | 0.82 | PDE10A (0.44) | ALDH1A1KDM4EMAPTPDE10AHPGD | |
| SCHEMBL9384223 | 0.82 | DDAH1 (0.58) | ALDH1A1KDM4EPDE10AHPGDLMNA | |
| SCHEMBL9178002 | 0.79 | GAA (0.60) | ALDH1A1KDM4EMAPTPDE10AHPGD | |
| SCHEMBL9179087 | 0.79 | RAB9A (0.50) | ALDH1A1KDM4EPDE10AHPGDGLA | |
| SCHEMBL1161627 | 0.78 | PARP1 (0.47) | ALDH1A1KDM4EHPGDLMNASMN1; SMN2 | |
| SCHEMBL1161334 | 0.78 | LMNA (0.46) | ALDH1A1KDM4EHPGDLMNASMN1; SMN2 | |
| SCHEMBL8626590 | 0.78 | EGFR (0.46) | ALDH1A1KDM4EMAPTPDE10AHPGD | |
| SCHEMBL30014118 | 0.77 | NPC1 (0.52) | ALDH1A1KDM4EMAPTPDE10AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12319684-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2025-06-03 | — | — | US | disclosed |
| US-20210363142-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2021-11-25 | — | — | US | disclosed |
| US-20210363142-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2021-11-25 | — | — | US | disclosed |
| US-10988475-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200354355-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE | 2020-11-12 | — | — | US | disclosed |
| US-10570128-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-02-25 | — | — | US | disclosed |
| US-10570128-B2 | Agonists of the apelin receptor and methods of use thereof | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170197958-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2017-07-13 | — | — | US | disclosed |
| US-20170197958-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2017-07-13 | — | — | US | disclosed |
| US-20170197958-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | Sanford Burnham Prebys Medical Discovery Institute | 2017-07-13 | — | — | US | disclosed |
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | BALLELL-PAGES LLUIS | 2010-07-22 | — | — | US | disclosed |
| US-7732460-B2 | Heterocyclic compounds, their preparation and their use as antibacterials | GLAXO GROUP LIMITED (GB) | 2010-06-08 | — | — | US | disclosed |
| EP-1963324-B1 | HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS ANTIBACTERIALS | GLAXO GROUP LTD (GB) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009036057-A1 | ANTIPROLIFERATIVE AGENTS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| WO-2009036057-A1 | ANTIPROLIFERATIVE AGENTS CONTAINING A ZINC BINDING MOIETY | CURIS, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090036433-A1 | Heterocyclic Compounds, their Preparation and their Use as Antibacterials | GLAXO GROUP LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
| EP-2005995-A1 | Heterocyclic compounds for the treatment of tuberculosis | GLAXO GROUP LIMITED (GB) | 2008-12-24 | — | — | EP | disclosed |
| US-20070185153-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210363142-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | APLNR, AGTR1, AGTR2 | ALDH1A1 2095/4885KDM4E 4185/4885MAPT 4140/4885 |
| US-10570128-B2 | Agonists of the apelin receptor and methods of use thereof | APLNR, AGTR1, AGTR2 | ALDH1A1 2095/4885KDM4E 4185/4885MAPT 4140/4885 |
| US-12319684-B2 | Agonists of the apelin receptor and methods of use thereof | APLNR, AGTR1, AGTR2 | ALDH1A1 2095/4885KDM4E 4185/4885MAPT 4140/4885 |
| US-20070185153-A1 | COMPOUNDS | NRDC, NISCH, MRPL21 | ALDH1A1 4225/4885KDM4E 4293/4885MAPT 1138/4885 |
| US-10988475-B2 | Agonists of the apelin receptor and methods of use thereof | APLNR, AGTR1, AGTR2 | ALDH1A1 2095/4885KDM4E 4185/4885MAPT 4140/4885 |
| US-20170197958-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | APLNR, AGTR1, AGTR2 | ALDH1A1 2095/4885KDM4E 4185/4885MAPT 4140/4885 |
| US-20100184751-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | SDHA, SDHB, NNT | ALDH1A1 1245/4885KDM4E 3949/4885MAPT 1280/4885 |
| US-20200354355-A1 | AGONISTS OF THE APELIN RECEPTOR AND METHODS OF USE THEREOF | APLNR, AGTR1, AGTR2 | ALDH1A1 2095/4885KDM4E 4185/4885MAPT 4140/4885 |
| US-20090036433-A1 | Heterocyclic Compounds, their Preparation and their Use as Antibacterials | MRPL21, NACA, NISCH | ALDH1A1 2482/4885KDM4E 4122/4885MAPT 3180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.